Hanming Wang

Hanming Wang

Auto-generated profile, based on publicly available information

Hanming Wang

Laboratory of Nucleic Acid Technology, Institute of Molecular Medicine, Peking University, Beijing, 100871, China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2012 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Open access
PDF file
MLMing Liu
Ming Liu
YWYun Wang
Yun Wang
HWHan‐Ming Wang
Han‐Ming Wang
YBYang Bai
Yang Bai
XZXinhua Zhang
Xinhua Zhang
HWHuai‐Liang Wang
Huai‐Liang Wang
Epidemiological data have shown that methamphetamine (MA) abuse significantly increases the risk of developing pulmonary arterial hypertension (PAH). To investigate whether MA could induce PAH and its possible mechanism, rats were exposed daily to MA for 5 weeks in the absence or presence of fluoxetine. The results showed that the pulmonary arterial pressure was not significantly increased, but the pulmonary arterial remodelling was markedly developed in the MA exposure group. The protein expressions of the serotonin transporter (5‐HTT) and 5‐HT1B receptor were increased in the lungs and in the pulmonary arteries of MA‐treated rats. Fluoxetine attenuated the pulmonary arterial remodelling and down‐regulated the protein expression of 5‐HTT and 5‐HT1B receptor in pulmonary arteries of MA‐treated rats. These findings suggest that fluoxetine has a novel potential suppressive effect on the chronic MA‐induced pulmonary vascular remodelling and also suggest that 5‐HTT and 5‐HT1B receptor may be involved as part of its mechanism.

1 October 2021 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
HWHanming Wang
Hanming Wang
XSXinyun Song
Xinyun Song
CSChun Song
Chun Song
XWXiaoxia Wang
Xiaoxia Wang
HCHuiqing Cao
Huiqing Cao

1 February 2018 in Journal of Genetics and Genomics
Verified
Journal Article
Closed access
CSChun Song
Chun Song
HYHan Yan
Han Yan
HWHanming Wang
Hanming Wang
YZYan Zhang
Yan Zhang
HCHuiqing Cao
Huiqing Cao
Xiao-Li TianXiao-Li Tian
Xiao-Li Tian

1 December 2018 in Journal of the Chinese Medical Association
Verified
Journal Article
Open access
ZSZhan-Hong Song
Zhan-Hong Song
HWHan-Ming Wang
Han-Ming Wang
MLMing Liu
Ming Liu
YBYang Bai
Yang Bai
YWYun Wang
Yun Wang
HWHuai-Liang Wang
Huai-Liang Wang
Pulmonary arterial hypertension (PAH) is a complex pulmonary vasculature disease characterized by remodeling of the pulmonary vessels and a persistent increase in the pulmonary vascular resistance (PVR) with a poor prognosis. Serotonin increases the expression of S100A4/Mts1, which in turn stimulates the proliferation and migration of human pulmonary artery smooth muscle cells through the interaction with RAGE (receptor for advanced glycation end products) and thus S100A4/Mts1 has been implicated in the development of PAH in vitro. Fluoxetine, a selective serotonin re-uptake inhibitor has been shown to protect against PAH. The current study was designed to test whether S100A4 and its associated proteins connected in the development of PAH in vivo as well as to investigate the involvement of those proteins in the protective effect of fluoxetine against PAH. MCT-induced PAH models were established in Wistar rats by a single intraperitoneal injection of MCT (60 mg/kg). Fluoxetine (2 and 10 mg/kg/day) was intragastrically administered once a day for 3 weeks along with controls. The detection methods followed include Hematoxylin and Eosin (H&E) staining, immunohistochemistry, western blotting and real-time reverse transcription-polymerase chain reaction (RT-PCR). MCT induced pulmonary hypertension, pulmonary vascular remodeling, and right ventricular hypertrophy significantly increased the expressions of S100A4 and RAGE in the pulmonary arteries, lungs and right ventricle (RV). Fluoxetine dose-dependently inhibited MCT-induced pulmonary arterial hypertension, pulmonary vascular remodeling, and right ventricular hypertrophy and reduced the S100A4 and RAGE. Further analysis revealed that fluoxetine alleviated both the increase of p53, MMP13, MMP2 and MMP9 and the decrease of pp53Ser15 and MDM2 in lungs and RV tissues of MCT-induced PAH rats. From the present investigation it could be concluded that S100A4/Mts1 and its associated proteins are involved in the evolution of MCT-induced PAH in rats and fluoxetine inhibits MCT-induced PAH in rats mainly through S100A4/RAGE signaling axis and involved factors.